ResidenceTimer™ Off-the-Shelf Assays
Kinase Panel
The table contains an overview of kinase assays that are available for measurement of target residence time measurement.
| Kinase | Domain | Reference therapeutics | Preview details |
| ABL (ABL1) | full length | bosutinib, dasatinib, imatinib, ponatinib | [pdf] |
| AKT1 | catalytic domain | GSK690693 | [pdf] |
| AKT2 | catalytic domain | GSK690693 | [pdf] |
| ALK | cytoplasmic domain | alectinib, crizotinib | [pdf] |
| ALK [L1196M] | cytoplasmic domain | brigatinib, crizotinib | [pdf] |
| ALK [G1202R] | cytoplasmic domain | lorlatinib | [pdf] |
| AurA (AURKA) | full length | MK-5108, pan-Aurora inhibitors | [pdf] |
| AurB (AURKB)* | full length | MK-5108, pan-Aurora inhibitors | [pdf] |
| AXL | cytoplasmic domain | crizotinib, sunitinib | [pdf] |
| BMX | full length | bosutinib, dasatinib | [pdf] |
| BRAF | catalytic domain | dabrafenib, vemurafenib | [pdf] |
| BRK | full length | ibrutinib | [pdf] |
| BTK | full length | dasatinib, ibrutinib, ponatinib | [pdf] |
| BTK* | full length | dasatinib, ibrutinib, ponatinib | [pdf] |
| BTK [T316A] | full length | acalabrutinib, fenebrutinib | [pdf] |
| BTK [T316A]* | full length | fenebrutinib, ibrutinib | [pdf] |
| BTK [T474I] | full length | ibrutinib | [pdf] |
| BTK [T474I]* | full length | ARQ-531, ibrutinib | [pdf] |
| BTK [T474S]* | full length | ARQ-531, ibrutinib | [pdf] |
| BTK [C481S] | full length | fenebrutinib, ibrutinib | [pdf] |
| BTK [C481S]* | full length | fenebrutinib | [pdf] |
| CDC2 (CDK1)/CycA2 | full length | staurosporine, dinaciclib | [pdf] |
| CDK2/CycA2 | full length | dinaciclib, PHA-793887 | [pdf] |
| CDK2/CycE1 | full length | SNS-032 | [pdf] |
| CDK4/CycD1 | full length | dinaciclib | [pdf] |
| CDK4/CycD3 | full length | abemaciclib, dinaciclib, palbociclib, ribociclib | [pdf] |
| CDK5/p25 | full length | dinaciclib, SNS-032 | [pdf] |
| CDK6/CycD1 | full length | dinaciclib | [pdf] |
| CDK7/CycH/MAT1 | full length | dinaciclib, pan-CDK inhibitors | [pdf] |
| CDK8/CycC | full length | staurosporine | [pdf] |
| CDK9/CycK | full length | dinaciclib, PHA-793887 | [pdf] |
| CDK9/CycT1 | full length | dinaciclib, pan-CDK inhibitors | [pdf] |
| CDK9/CycT2 | full length | staurosporine, dinaciclib | [pdf] |
| CHK1 (CHEK1) | full length | bosutinib, sunitinib | [pdf] |
| CSF-1R/FMS | cytoplasmic domain | dasatinib | [pdf] |
| DDR2* | cytoplasmic domain | dasatinib, imatinib, ponatinib, sorafenib | [pdf] |
| EGFR | cytoplasmic domain | afatinib, erlotinib, gefitinib | [pdf] |
| EGFR [d746-750] | cytoplasmic domain | gefitinib, erlotinib, afatinib | [pdf] |
| EGFR [d746-750/C797S] | cytoplasmic domain | gefitinib, erlotinib, afatinib | [pdf] |
| EGFR [T790M] | cytoplasmic domain | afatinib | [pdf] |
| EGFR [T790M/L858R] | cytoplasmic domain | osimertinib | [pdf] |
| EGFR [C797S/L858R] | cytoplasmic domain | gefitinib, erlotinib, afatinib | [pdf] |
| EGFR [L858R] | cytoplasmic domain | afatinib | [pdf] |
| EPHA2 | cytoplasmic domain | BMS-777607, dasatinib, staurosporine | [pdf] |
| FAK (PTK2) | truncated human | crizotinib | [pdf] |
| FGFR1 | cytoplasmic domain | infigratinib, ponatinib | [pdf] |
| FGFR1* | cytoplasmic domain | infigratinib, ponatinib | [pdf] |
| FGFR2 | cytoplasmic domain | infigratinib | [pdf] |
| FGFR3* | cytoplasmic domain | infigratinib, sunitinib | [pdf] |
| FGFR4 | cytoplasmic domain | infigratinib, sunitinib | [pdf] |
| FLT3 | cytoplasmic domain | dasatinib, imatinib | [pdf] |
| FYN [isoform a] | full length | dasatinib, ponatinib, regorafenib | [pdf] |
| GCN2 (EIF2AK4) | full length | A-92 | [pdf] |
| GSK3β (GSK3B) | full length | abemaciclib, staurosporine | [pdf] |
| HPK1 (MAP4K1) | catalytic domain | bosutinib | [pdf] |
| IGF1R* | catalytic domain | cabozantinib, GSK-1838705, staurosporine | [pdf] |
| IKKα (CHUK) | full length | IKKβ inhibitor | [pdf] |
| IKKα (CHUK) [K44A] inactive | full length | IKKβ inhibitor | [pdf] |
| IRAK4 | full length | crizotinib, sunitinib | [pdf] |
| Kinase | Domain | Reference therapeutics | Preview details |
| ITK* | full length | crizotinib, sunitinib | [pdf] |
| JAK2 | catalytic domain | staurosporine | [pdf] |
| KDR (VEGFR2) | cytoplasmic domain | vandetanib | [pdf] |
| KIT* | cytoplasmic domain | masitinib, pazopanib, staurosporine | [pdf] |
| LCK | full length | ponatinib, regorafenib | [pdf] |
| LYNa | full length | ponatinib, regorafenib, tamatinib | [pdf] |
| MAP2K1 inactive | full length | crizotinib, dasatinib, trametinib | [pdf] |
| MAP3K5 | catalytic domain | bosutinib, staurosporine, sunitinib | [pdf] |
| MER | cytoplasmic domain | BMS-777607 | [pdf] |
| MET | cytoplasmic domain | crizotinib | [pdf] |
| p38α (MAPK14) | truncated human | sorafenib, p38 MAPK inhibitors | [pdf] |
| p38α (MAPK14) inactive | truncated human | sorafenib, p38 MAPK inhibitors | [pdf] |
| PAK4 | full length | bosutinib, GSK690693, staurosporine | [pdf] |
| PDGFRα (PDGRFA) | cytoplasmic domain | nintedanib, axitinib, crenolanib, gilteritinib | [pdf] |
| PDGFRα (PDGRFA)* | cytoplasmic domain | nintedanib, axitinib, crenolanib, gilteritinib | [pdf] |
| PDGFRβ (PDGRFB) | cytoplasmic domain | nintedanib, axitinib, crenolanib, gilteritinib | [pdf] |
| PDGFRβ (PDGRFB)* | cytoplasmic domain | nintedanib, axitinib, crenolanib, gilteritinib | [pdf] |
| PIK3CA/PIK3R1 | full length | dactolisib, pictilisib | [pdf] |
| PIK3CA [R88Q]/PIK3R1* | full length | idelalisib | [pdf] |
| PIK3CA [P539R]/PIK3R1* | full length | idelalisib | [pdf] |
| PIK3CA [E542K]/PIK3R1* | full length | idelalisib | [pdf] |
| PIK3CA [E545K]/PIK3R1* | full length | idelalisib | [pdf] |
| PIK3CA [H1047R]/PIK3R1* | full length | idelalisib | [pdf] |
| PIK3CB/PIK3R1 | full length | apitolisib | [pdf] |
| PIK3CD/PIK3R1 | full length | duvelisib, idelalisib | [pdf] |
| PIK3CG | full length | apitolisib, dactolisib, duvelisib | [pdf] |
| PIK3CG/PIK3R5 | full length | apitolisib, duvelisib | [pdf] |
| PKACa (PRKACA) | full length | A-674563 | [pdf] |
| PKN1 | full length | GSK690693 | [pdf] |
| PLK1 | full length | GSK461364 | [pdf] |
| PYK2 (PTK2B)* | full length | crizotinib | [pdf] |
| RAF1 (CRAF) | catalytic domain | dabrafenib | [pdf] |
| RET | cytoplasmic domain | dasatinib, ponatinib, regorafenib, sorafenib, vandetanib | [pdf] |
| RET [G691S]* | cytoplasmic domain | staurosporine | [pdf] |
| RET [Y791F]* | cytoplasmic domain | staurosporine | [pdf] |
| RET [V804M] | cytoplasmic domain | staurosporine | [pdf] |
| RET [V804M]* | cytoplasmic domain | staurosporine | [pdf] |
| RET [S891A]* | cytoplasmic domain | staurosporine | [pdf] |
| RET [M918T]* | cytoplasmic domain | staurosporine | [pdf] |
| ROCK1 | catalytic domain | GSK 429286A | [pdf] |
| SRC | full length | A770041, ponatinib, regorafenib | [pdf] |
| SRPK1 | full length | staurosporine | [pdf] |
| SYK | full length | staurosporine | [pdf] |
| SYK* | full length | staurosporine | [pdf] |
| TGFβR1 (TGFBR1) | catalytic domain | SB 431542 | [pdf] |
| TIE2* | cytoplasmic domain | ponatinib, vandetanib | [pdf] |
| TNIK | catalytic domain | bosutinib, sunitinib | [pdf] |
| TRKA (NTRK1) | cytoplasmic domain | AZ23, ponatinib | [pdf] |
| TRKA (NTRK1)* | cytoplasmic domain | AZ23, ponatinib | [pdf] |
| TRKB (NTRK2) | cytoplasmic domain | ponatinib | [pdf] |
| TRKB (NTRK2)* | cytoplasmic domain | AZ23, ponatinib | [pdf] |
| TRKC (NTRK3)* | catalytic domain | AZ23, sorafenib | [pdf] |
| TYRO3 | cytoplasmic domain | BMS-777607 | [pdf] |
| TYRO3* | cytoplasmic domain | BMS-777607 | [pdf] |
| WEE1 | catalytic domain | AZD1775 | [pdf] |
| YES (YES1) | full length | saracatinib, staurosporine | [pdf] |